This is a 6 page article:
Introduction Can Schedule/Sequence Alterations Affect Outcomes? Evaluating New Therapeutic Regimens in the Metastatic Setting Future Directions in Chemotherapeutic Management Conclusions References http://www.medscape.com/viewarticle/491728 |
Great article Merridith.
One thing all of these articles refers to is Response Rate, Time to Disease Progression (TTP), and Overall Survival (OS). My question is: many of these novel therapies or novel combinations have a significantly different TTP but have a non-significant OS. In otherwords, why is it if we can stall the TTP you still died just as early as the lower TTP study arm? Is this a statistical anomoly or a medical fact? Al |
All times are GMT -7. The time now is 01:25 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021